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Abstract 
Background:  Amifostine is a pharmaceutical agent that is used clinically to counteract the side-effects of chemotherapy and 
radiotherapy. It acts as a free radical scavenger that protects against harmful DNA cross-linking. The purpose of this study was to 
determine the effect of amifostine on the development of skin cancer in xeroderma pigmentosum (XP) mice exposed to ultraviolet B 
radiation (UVB). 
Methods:  Twenty-five XP mice were equally divided into five groups. Group 1 (control) received no amifostine and no UVB exposure. 
Group 2 also received no amifostine, but was exposed to UVB at a dose of 200 mJ/cm
2 every other day. The remaining groups were 
subjected to the same irradiation, but were given amifostine at a dose of 50 mg/kg (group 3), 100 mg/kg (group 4), or 200 mg/kg (group 
5) immediately prior to each exposure. 
Results:  No tumours were seen in the control group. The animals in group 2 (no amifostine) developed squamous cell carcinoma (SCC) 
at 3.5–4.5 months (mean 3.9 months). Groups 3 and 4 (low- and medium-dose amifostine) developed SCC at 4.0–7.0 months (mean 5.3 
months), representing a statistically significant delay in tumour presentation (p = 0.04). An even greater delay was seen in group 5 (high-
dose amifostine), which developed SCC at 7.0–9.0 months (mean 8.5 months, p < 0.001 versus groups 3 and 4). Ocular keratitis 
developed in all animals except the unexposed controls and the high-dose treatment group. 
Conclusion:  Treatment with amifostine significantly delays the onset of skin cancer and prevents ocular keratitis in UVB-exposed XP 
mice. 
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Introduction 
Skin cancer is the most common malignancy in the United 
States, affecting over one million patients annually and 
representing one-third of all cancer diagnoses [1]. Exposure to 
solar ultraviolet radiation, particularly ultraviolet B (UVB), is the 
predominant cause of most skin cancers acting through 
mechanisms of DNA damage (either directly or via free-radical 
generation) and immune system inhibition [2, 3]. The 
development of skin cancer is also linked to several patient 
characteristics, including fair skin, light hair and eye colour, the 
tendency to burn rather than tan, and family history [2]. 
The combination of individual susceptibility and environmental 
exposure is particularly devastating to patients with xeroderma 
pigmentosum (XP), a disorder characterized by an inability to 
repair damaged DNA. Patients with this disorder have a 1000-
fold increased incidence—and essentially a 100% lifetime 
incidence—of skin cancer, usually presenting at a young age 
[4]. Standard measures for skin cancer prevention, such as sun 
avoidance, protective clothing, and sunscreens, are inadequate 
in XP patients [5], underscoring the need for more effective 
prophylaxis. 
Amifostine (Ethyol; MedImmune, Inc., Gaithersburg, MD), is an 
aminothiol compound known for its cytoprotective effects. Its 
active metabolite is an intracellular free radical scavenger that 
prevents interstrand DNA crosslinking. Originally developed by 
the military during the Cold War to protect personnel from 
radiation sickness, it has since been used clinically to 
ameliorate the side effects of chemotherapy and radiotherapy 
[6]. Given its ability to scavenge free radicals and to protect 
DNA architecture, we hypothesized that amifostine could inhibit 
the development of skin cancer in XP mice exposed to UVB. 
 
Materials and methods 
This protocol was approved by the Animal Care and Use 
Committee (ACUC) of the University of Missouri-Columbia. 
Twenty-five XP mice aged 7–8 weeks were randomly divided 
into five equal groups (Table 1). The animals in group 1 served 
as controls, receiving no UVB exposure and no treatment with 
amifostine. The animals in group 2 were exposed to UVB every 
other day at a dose of 200 mJ/cm
2 (10 mJ/cm
2/min for 20 
minutes), using a Panasol II UVB lamp (National Biological 
Corp., Twinsling, OH). They received intraperitoneal injections 
of saline prior to each exposure, and thus served as a placebo 
group. The remaining three groups received the same 
irradiation, but were treated with intraperitoneal injections of 
amifostine prior to each exposure. In group 3, the animals 
received amifostine at a low dose of 50 mg/kg; in group 4, a 
medium dose of 100 mg/kg; and in group 5, a high dose of 200 
mg/kg. The high dose was well below the reported LD50 for 
amifostine in mice (550-1140 mg/kg) [6]. 
The animals were housed in our institution’s animal care facility 
according to ACUC guidelines and had minimal additional 
ultraviolet exposure. They were examined every other day, at 
the time of their injections and irradiation, and suspicious 
lesions were biopsied. The study was continued until all non-
control animals had developed skin cancer, which occurred at 
nine months. At this time all animals were euthanized and 
additional lesions were biopsied. 
Statistical calculations were performed with one-way analysis of 
variance using the Holm–Sidak method of pair-wise multiple 
comparison procedures. 
 
Results 
Three animals died during the course of the study. One animal 
from group 4 (medium-dose amifostine) and one from group 5 
(high-dose amifostine) died at approximately two months as a 
result of intrasplenic injection. Postmortem examination 
revealed no evidence of malignancy in either animal; however, 
they were excluded from statistical analysis because the 
remaining subjects in their respective groups developed 
tumours in a significantly later timeframe. The third animal, from 
group 2 (placebo), died as a result of complications from 
metastatic squamous cell carcinoma (SCC) after four months of 
UVB exposure. 
No tumours were seen in any of the control animals (group 1). 
All of the UVB-exposed animals, with the exception of the two 
that died early from intrasplenic injections, developed SCC (Fig. 
1). No other types of skin cancer (e.g., basal cell carcinoma or 
melanoma) were identified. 
SCC was first seen in group 2 (placebo) at 3.5 months, with all 
animals affected by 4.5 months (mean 3.9 months). 
SCC appeared in group 3 (low-dose amifostine) at 4.0–7.0 
months (mean 5.5 months). The surviving animals in group 4 
(medium-dose amifostine) developed SCC in a similar
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Table 1: Mean time to tumour development in ultraviolet B-exposed xeroderma pigmentosum mice.  Error bars indicate the range of onset.  No 
tumours developed in non-exposed controls. 
0123456789
High-dose amifostine
Medium-dose amifostine
Low-dose amifostine
No amifostine
Time (months)
 
 
 
Figure 1: No tumours developed in non-exposed control mice (above, left) throughout the nine-month study period.  Squamous cell carcinoma 
developed in all ultraviolet B-exposed mice, most commonly on the ears (above, right) and nose (below, left).  All ultraviolet B-exposed mice 
developed ocular keratitis (below, left and right), with the exception of those receiving high-dose amifostine.
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timeframe (4.0-7.0 months, mean 5.1 months). This onset 
represents a statistically significant delay in tumour presentation 
compared to group 2 (placebo) (p = 0.04). 
An even greater delay was seen in the surviving members of 
group 5 (high-dose amifostine), which developed SCC at 7.0–
9.0 months (mean 8.5 months). When compared to the onset in 
groups 3 and 4, this delay was highly statistically significant (p < 
0.001) (Table 1). 
In addition to SCC, ocular keratitis developed in all animals 
except those in group 1 (non-exposed controls) and group 5 
(high-dose amifostine) (Fig. 1). Despite the keratitis, no ocular 
tumours were identified in any of the animals.0 
 
Discussion 
This study demonstrated the chemopreventive capacity of 
amifostine in the setting of UVB exposure. 
Chemoprevention is the use of chemical agents to prevent the 
development of cancer [7]. As summarized by Harris and 
Alberts [8], the ideal chemopreventive agent displays minimal 
toxicity in healthy tissues and can differentiate cancerous from 
healthy cells. In addition, it should be tailored to act within the 
carcinogenic cascade of a particular malignancy in order to 
have a “rational mechanism of action”.  In designing this study, 
amifostine was thought to fulfil these criteria and to be an 
appropriate chemopreventive agent in the development of UVB-
induced skin cancer. 
Amifostine was developed by the Walter Reed Army Institute of 
Research in the 1970s as part of a classified project 
investigating agents that could be used to protect military 
personnel in the event of a nuclear war [9]. Amifostine had the 
greatest radioprotective capability and the best safety profile of 
4,400 compounds evaluated at that time [6]. Its active 
metabolite is generated by the interaction of the parent drug 
with membrane-bound alkaline phosphatase. Because this 
enzyme is usually present only in normal tissues, the active 
metabolite is able to enter only healthy cells, where it exerts at 
least two cytoprotective actions: scavenging of free radicals 
(generated chemically or by ionizing radiation) [10] and 
prevention of interstrand DNA crosslinking [11].
 
Either or both of these actions may be responsible for the 
cytoprotective effect of amifostine on keratinocytes. Like all 
other cancers, SCC follows a step-wise progression from 
normally functioning cells to malignant neoplasm. In the case of 
SCC, the transformation begins with actinic keratosis, which 
transitions to carcinoma in situ, and, finally, to SCC [12]. The 
instigating factors are variable and can involve free radical 
damage, pyrimidine dimer formation, DNA repair defects, and 
mutations in tumour suppressor genes [13, 14]. Each step of 
this progression is necessary for tumour formation, and each 
step could theoretically be blocked by the action of amifostine. 
The XP mouse is at significantly increased risk for the 
development of skin cancer (particularly SCC) due to its inability 
to repair damaged DNA [4]. Because disease progression was 
significantly delayed, it is probable that amifostine functioned as 
a DNA protectant as described above, but was overwhelmed by 
the UVB effect in this highly susceptible population. A similar 
pattern was evident with regard to ocular keratitis, a condition 
seen in about 40% of XP patients [15], but in none of the 
animals in the high-dose treatment group. This observation 
further supports the presumption that amifostine at the studied 
doses inhibited DNA damage in this model, but was not 
completely adequate in cutaneous tissues. 
Sunscreens and photoprotective clothing are the current 
mainstays in the prevention of solar radiation-induced skin 
cancer.  While both modalities can be protective, compliance is 
often impractical and sporadic, limiting their clinical 
effectiveness [16–18].  Various dietary interventions have also 
been recommended as a means of preventing skin cancer [19], 
but in most cases (including supplementation with selenium, 
beta-carotene, and vitamin E), scientific trials have failed to 
demonstrate a chemopreventive potential [20–22]. Notable 
exceptions include dietary supplementation with retinoids and 
restriction of dietary fat, which have both been shown to 
produce a modest reduction in the incidence of skin cancer [23, 
24]. Nonetheless, currently available prophylaxis against skin 
cancer is greatly limited, making effective chemoprevention an 
attractive addition to the clinical armamentarium. 
Amifostine is currently approved for the reduction of cisplatin-
induced nephrotoxicity in patients being treated for ovarian or 
lung cancer, and radiation-induced xerostomia in patients being 
treated for head and neck cancer. It is administered as an 
intravenous infusion shortly before chemotherapy or 
radiotherapy. The recommended starting dose is 910 mg/m
2 
(approximately 25 mg/kg in the average adult), with a maximum 
dose of 1300 mg/m
2 (approximately 35 mg/kg). The most 
common adverse reactions are transient hypotension and 
nausea/vomiting [25]. Although the doses used in this study 
were well below the LD50 for mice, they were substantially 
above the recommended doses for humans [6]. This fact 
represents an obvious hurdle in the clinical application of 
amifostine as a chemopreventive option for humans, as does 
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the current availability of amifostine only as an intravenous 
infusion. Nonetheless, amifostine appears to be an efficacious 
and well-tolerated chemopreventive agent in XP mice, and with 
further study and development may become a feasible option 
for humans, as well. 
A limitation of this study is its rather small number of subjects. 
Although preliminary analysis indicated a sufficient quantity in 
each group, the loss of two subjects from iatrogenic injury may
have compromised the power of the study. Thus, while our 
results were both statistically significant and logically consistent, 
further and more extensive investigations are clearly warranted. 
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